Bioventix (LON:BVXP – Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported GBX 145.74 EPS for the quarter, Digital Look Earnings reports. The business had revenue of GBX 1,297 million during the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%.
Bioventix Stock Down 0.9%
Bioventix stock opened at GBX 1,972 on Wednesday. Bioventix has a 12 month low of GBX 1,300 and a 12 month high of GBX 2,255. The stock has a market cap of £103.04 million, a P/E ratio of 14.03 and a beta of 0.54. The company’s fifty day simple moving average is GBX 1,703.32 and its 200-day simple moving average is GBX 1,656.96.
Bioventix Company Profile
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Read More
- Five stocks we like better than Bioventix
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.
